264 related articles for article (PubMed ID: 17286273)
1. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Aug; 97(6):1376-86. PubMed ID: 17286273
[TBL] [Abstract][Full Text] [Related]
2. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
J Pharmacol Exp Ther; 2010 Jun; 333(3):961-9. PubMed ID: 20233799
[TBL] [Abstract][Full Text] [Related]
3. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
Biotechnol Bioeng; 2008 Feb; 99(2):475-84. PubMed ID: 17680664
[TBL] [Abstract][Full Text] [Related]
4. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Feb; 96(2):381-91. PubMed ID: 16937408
[TBL] [Abstract][Full Text] [Related]
5. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Wang Y; Pardridge WM
Biotechnol Bioeng; 2008 Jun; 100(2):387-96. PubMed ID: 18080333
[TBL] [Abstract][Full Text] [Related]
6. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
7. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.
Lu JZ; Hui EK; Boado RJ; Pardridge WM
Bioconjug Chem; 2010 Jan; 21(1):151-6. PubMed ID: 20000684
[TBL] [Abstract][Full Text] [Related]
8. A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery.
Boado RJ
Drug News Perspect; 2008 Nov; 21(9):489-503. PubMed ID: 19180267
[TBL] [Abstract][Full Text] [Related]
9. CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
Biotechnol Bioeng; 2011 Jan; 108(1):186-96. PubMed ID: 20803562
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.
Hui EK; Boado RJ; Pardridge WM
Mol Pharm; 2009; 6(5):1536-43. PubMed ID: 19624167
[TBL] [Abstract][Full Text] [Related]
11. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses.
Pardridge WM
Bioconjug Chem; 2008 Jul; 19(7):1327-38. PubMed ID: 18547095
[TBL] [Abstract][Full Text] [Related]
12. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
Bioconjug Chem; 2008 Mar; 19(3):731-9. PubMed ID: 18278853
[TBL] [Abstract][Full Text] [Related]
13. Biopharmaceutical drug targeting to the brain.
Pardridge WM
J Drug Target; 2010 Apr; 18(3):157-67. PubMed ID: 20064077
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor.
Boado RJ; Lu JZ; Hui EK; Sumbria RK; Pardridge WM
Biotechnol Bioeng; 2013 May; 110(5):1456-65. PubMed ID: 23192358
[TBL] [Abstract][Full Text] [Related]
15. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.
Zhou QH; Boado RJ; Pardridge WM
J Drug Target; 2012 Sep; 20(8):715-9. PubMed ID: 22845843
[TBL] [Abstract][Full Text] [Related]
16. Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey.
Boado RJ; Hui EK; Lu JZ; Sumbria RK; Pardridge WM
Bioconjug Chem; 2013 Oct; 24(10):1741-9. PubMed ID: 24059813
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
J Biotechnol; 2010 Mar; 146(1-2):84-91. PubMed ID: 20100527
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein.
Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2010 Nov; 1360():193-7. PubMed ID: 20833153
[TBL] [Abstract][Full Text] [Related]
19. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
[TBL] [Abstract][Full Text] [Related]
20. Insulin Receptor Antibody-α-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type B Fibroblasts.
Boado RJ; Lu JZ; Hui EK; Lin H; Pardridge WM
Mol Pharm; 2016 Apr; 13(4):1385-92. PubMed ID: 26910785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
